Hearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11-15

ACOUSIA THERAPEUTICS GMBH, AND ITS PARTNERS FROM THE TRANSLATIONAL HEARING RESEARCH GROUP AT THE TÜBINGEN HEARING RESEARCH CENTER (DEPARTMENT OF OTOLARYNGOLOGY, HEAD AND NECK SURGERY, UNIVERSITY OF TÜBINGEN), WILL PRESENT DATA ON ITS LEAD CANDIDATES — CLINICAL STAGE ACOU085 AND LATE PRECLINICAL STAGE ACOU082 — IN TWO PRESENTATIONS AT THE 46TH ANNUAL MIDWINTER MEETING OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY IN ORLANDO (FL) ON FEBRUARY 11–15, 2023.

SMALL-MOLECULE KV7.4 ACTIVATOR ACOU085 PROTECTS AGAINST CISPLATIN-INDUCED HEARING LOSS AND OUTER HAIR CELL DEATH IN A GUINEA PIG MODEL

ACOU085 is a proprietary small molecule, etiology-agnostic otoprotective drug candidate, expected to finish a first-in-man clinical Phase 1b study by late 2022 using standard transtympanic administration of a slow-release gel formulation. The ACOU085 presentation at the 2023 MidWinter Meeting will focus on preclinical pharmacology data from a guinea pig cisplatin-induced ototoxicity model, which supports the potential of ACOU085 treatment for preventing chemotherapy-induced hearing loss and outer hair cell apoptosis in cancer patients.

ACOU082: A UNIQUE, SYSTEMICALLY ADMINISTERED KV7.4 ACTIVATOR DRUG CANDIDATE FOR THE TREATMENT AND PREVENTION OF AGE-RELATED HEARING LOSS

ACOU082 is a proprietary small molecule Kv7.4 developed for oral administration with the potential to both acutely enhance natural hearing and preserve hearing capacity against e.g. age-related hearing loss. The ACOU082 presentation focuses on a proof-of-concept study using the senescence-accelerated mouse (SAMP8) model, which demonstrates the ability of chronic, systemic ACOU082 administrations to significantly enhance hearing sensitivity after just short-term treatment. Furthermore, ACOU082 also significantly reduced the progression of age-related hearing loss as measured by ABR threshold shifts and compared to a placebo-treated, vehicle control group.

Kv7.4 channels are strongly expressed in the sensory outer hair cells of the cochlea, where they not only influence outer hair cell amplification and frequency discrimination to maintain hearing function, but also provide homeostatic resistance to deleterious insults like drug-induced ototoxicity, noise exposure, and aging.

ABOUT ACOUSIA THERAPEUTICS GMBH

Acousia Therapeutics GmbH is a privately-held, clinical stage biotech company based in Tübingen, Germany. The company is dedicated to the identification and development of small molecules for effective prevention and treatment of different etiologies of hearing loss. Acousia Therapeutics develops drugs for local and systemic administration.

CONTACT Tim Boelke, M.D.

boelke@acousia.com +49 70712988186

www.acousia.com

View original content:https://www.prnewswire.co.uk/news-releases/hearing-loss-company-acousia-therapeutics-to-present-data-for-lead-candidates-acou085–acou082-at-aro-2023-midwinter-meeting-february-1115-301686564.html

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender

Das könnte dir auch gefallen
%d Bloggern gefällt das: